S 2842
Stop CMV Act of 2025
Take action
Record your position on this measure.
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
```json { "summary": "The Stop CMV Act of 2025 aims to improve the detection of congenital Cytomegalovirus (CMV) in newborns. It requires hospitals and healthcare facilities to offer CMV screening to infants 21 days or less old, with states responsible for establishing testing procedures and disseminating information to parents. The bill also provides funding through grants to states and the CDC for data collection, training, and public awareness campaigns, as well as research into screening techniques, prevention, and treatments for CMV.", "keyProvisions": [ "Requires hospitals to screen newborns for congenital CMV.", "States must establish standards and procedures for CMV testing and information dissemination.", "Provides grants to states for administering testing and sup
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.
119th CONGRESS — 1st Session
S. 2842
IN THE SENATE OF THE UNITED STATES
A BILL
To amend the Public Health Service Act to provide for congenital Cytomegalovirus screening of newborns.
This Act may be cited as Stop CMV Act of 2025
.
Part A of title XI of the Public Health Service Act is amended by inserting after section 1116 (42 U.S.C. 300b–15) the following:
Each hospital or other health care entity caring for infants who are 21 days or less of age (as designated by the Secretary) may administer, or cause to have administered, to every such infant in its care a test for congenital Cytomegalovirus in accordance with this section.
In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures for the administration of testing under subsection (a), including recording the results of such tests, tracking activities, conducting follow-up reviews, and carrying out educational activities.
In carrying out this section, the chief executive officer for health in each State may prescribe standards and procedures setting forth the manner in which testing information is disseminated to a parent or guardian of the infant to be tested.
If a State has not prescribed standards and procedures that are approved as provided for in paragraph (4) by the date that is 2 years after the date of enactment of the
Stop CMV Act of 2025
, the Discretionary Advisory Committee on Heritable Disorders in Newborns and Children established under section 1111 (referred to in this section as theAdvisory Committee) shall prescribe appropriate standards and procedures which may be implemented by such State.
The standards and procedures prescribed under this subsection shall be subject to review and approval by the Advisory Committee. In reviewing or prescribing standards and procedures as required under this subsection, the Advisory Committee shall consider standards and procedures adopted in other States with respect to the screening of congenital Cytomegalovirus, the standards and procedures adopted in such State with respect to the screening of infants for other heritable diseases, and any scientific evidence the Advisory Committee considers relevant to provide for the screening of infants for congenital Cytomegalovirus.
The Secretary, acting through the Administrator of the Health Resources and Services Administration, shall award grants to States that prescribe standards and procedures in accordance with paragraphs (1) and (2), to be distributed by the States to entities described in subsection (a) to administer tests in accordance with that subsection.
There is authorized to be appropriated to carry out subparagraph (A) such sums as may be necessary for each of fiscal years 2026 and 2027.
The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award grants to, or enter into cooperative agreements with, States to provide technical assistance to State agencies or designated entities of States—
to develop, maintain, and improve data collection systems relating to congenital Cytomegalovirus; and
to assist in the education and training of health care providers, patients, and the general public regarding the risk reduction or prevention, symptoms, diagnosis, and treatment of congenital Cytomegalovirus, including, as necessary, through the publication of scientific, evidence-based educational materials on internet webpages maintained by State agencies or designated entities of States.
There is authorized to be appropriated to carry out subparagraph (A) such sums as may be necessary for each of fiscal years 2026 and 2027.
for the purposes of this section, establish a program, or expand existing programs, of research and development on the efficacy of new screening techniques and technology relating to congenital Cytomegalovirus, including clinical studies of screening methods, studies on efficacy of intervention, and related research; and
establish a program, or expand existing programs, of research and development into congenital Cytomegalovirus diagnostics, prevention, treatments including public health awareness campaigns, risk reduction, and vaccine development, and cures or treatments (during pregnancy and after birth).
Section 1111(b) of the Public Health Service Act (42 U.S.C. 300b–10(b)) is amended—
in paragraph (7) by striking and
after the semicolon;
by redesignating paragraph (8) as paragraph (9); and
by inserting after paragraph (7) the following:
carry out activities under section 1116A; and